Leaders in Pharmaceutical Business Intelligence (LPBI) Group

LIVE from Kresge Auditorium @MIT

Key concepts captured

• tRNA the intermediate between RNA and protein
• genes expressed by alternative promoters
• transcription units – RNA has katalitic roles: ribosome, spliceosome,RNA precursor to DNA
• 1998 RNA as a regulatory molecule
• biochemistry short RNAs silence by mRNA regulation
• Lamin A/C knock-down –>>>>>  silence any gene and any exon
• Treatment of disease  – nucleic acid delivery: viral vs non-viral – diseased genes
• nucleic acid as therapeutic agents
• Agent: modified antisense, siRNA conjugate mRNA, miRNA
• Biopharmaceutical – modular: nanoparticles, antibody, lipid nanoparticles, conjugated siRNA
• Pharmaceutical nucleic based drugs
• CRISPR/Cas: bacteria adaptive immune system
• Kingdom of life advanced by sequencing genes
• microRNA pathway and interference
• proposed anatomy of miRNA/mRNA interactions
• microRNA regulation in Cancer networks: over expression, underexpression
• Transcription Factors (TFs) and miRNA are master regulators – Chromatin
• Explosion in World of RNA: Technology, Genomics: Transcription of Genome – Regulation in biological systems, 100s molecules discovered: Long non-coding RNAs, no association with ribosome, absence of conserved ORF
• How common IncRNAs? mechanisms: LincRNA-p21 regulates p21 in CIS controlling cell cycle and polycomb target genes

9:10 – 9:30 Phillip Sharp  “Why RNA Biology?” Phillip Sharp, PhD  Institute Professor, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

@MIT – Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014 8:30AM – 4:30PM, Kresge Auditorium @MIT

http://ki.mit.edu/news/symposium

REALTIME event coverage for the Scientific Media by Dr.  A. Lev-Ari 

in Open Access Scientific Journal of Leaders in Pharmaceutical Business Intelligence (LPBI)

http://pharmaceuticalintelligence.com

#pharmaIT,#BIOIT,#technews,#curation,#pharmanews,#mobilehealth,#mhealth,#science,#science2_0,#healtcare,#BIOIT14,#Boston ,@Biotech News,@MhealthForAll,@mHealthAlliance,@HCtrends,@mobilehealth360,@science 2_0
Phillip A. Sharp is Institute Professor (highest academic rank) at the Massachusetts Institute of Technology and member of the Department of Biology and the Koch Institute for Integrative Cancer Research. He joined the Center for Cancer Research (now the Koch Institute) in 1974 and served as its director for six years, from 1985 to 1991, before taking over as head of the Department of Biology, a position he held for the next eight years. More recently, he was founding director of the McGovern Institute, a position he held from 2000 to 2004. His research interests have centered on the molecular biology of gene expression relevant to cancer and the mechanisms of RNA splicing. His landmark work in 1977 provided the first indications of “discontinuous genes” in mammalian cells. The discovery fundamentally changed scientists’ understanding of gene structure and earned Dr. Sharp the 1993 Nobel Prize in Physiology or Medicine. Dr. Sharp has authored over 400 papers. He is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, the American Philosophical Society, and the Royal Society, UK. Among his many awards are the Gairdner Foundation International Award, the Lasker Basic Medical Research Award and the National Medal of Science. His long list of service includes the presidency of the AAAS (2013) and Chair of the Scientific Advisory Committee, SU2C Project, AACR.  A native of Kentucky, Dr. Sharp earned a BA degree from Union College, Barbourville, KY, and a PhD in chemistry from the University of Illinois, Champaign-Urbana. Dr. Sharp is a co-founder of Biogen (now Biogen Idec) and Alnylam Pharmaceuticals Inc.